Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results

Key Points

• Telomir Pharmaceuticals reported quarterly EPS of -$0.79, reflecting continued losses at the clinical-stage biopharmaceutical company.
• Shares fell to $1.05, near the lower end of their 52-week range, giving the company a market capitalization of approximately $72.2 million.
• Analyst sentiment remains mixed, with one Buy, one Hold and one Sell rating; the overall consensus is Hold, while Weiss Ratings reiterated a “sell (e+)” rating.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, Zacks reports.

Telomir Pharmaceuticals Price Performance

Shares of Telomir Pharmaceuticals stock traded down $0.06 during trading on Thursday, reaching $1.05. 86,652 shares of the stock traded hands, compared to its average volume of 126,949. The company has a market capitalization of $72.22 million, a price-to-earnings ratio of -3.62 and a beta of -0.24. The business has a fifty day simple moving average of $1.22 and a two-hundred day simple moving average of $1.26. Telomir Pharmaceuticals has a 52-week low of $0.89 and a 52-week high of $2.09.

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company's stock valued at $61,000 after buying an additional 10,880 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $33,000. XTX Topco Ltd bought a new position in shares of Telomir Pharmaceuticals during the 4th quarter valued at approximately $53,000. Jane Street Group LLC bought a new position in shares of Telomir Pharmaceuticals during the 2nd quarter valued at approximately $62,000. Finally, Raymond James Financial Inc. grew its holdings in shares of Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company's stock valued at $105,000 after purchasing an additional 73,547 shares in the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Telomir Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold".

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc NASDAQ: TELO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company's lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source